Skip to Content
Privacy Policy.

" c-nmssatomrichtext_nmssatomrichtext-host="">

We use cookies to keep our site safe and provide an enhanced, personalized experience. You can choose to accept or manage optional cookies. More details about how we protect and use your information can be found in our Privacy Policy.

Driving Commercial Progress

The Fast Forward Program

Apply for Funding

Funding to Date

Fast Forward Application Process

Progress Highlights

Cadenza BioPotential drug promotes remyelination by interacting with a type of estrogen receptor
Therini BioPotential therapeutic antibody protects the nervous system from MS damage
Bionure Obtained favorable Phase 2 topline data in optic neuritis, often first symptom of MS

By using this website, you agree to our Terms of Use (last updated August 2025).

© 2025 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.

The National Multiple Sclerosis Society is proud to be a source of information on multiple sclerosis related topics. Unless otherwise indicated, the information provided is based on professional advice, published experience and expert opinion. However, the information does not constitute medical or legal advice. For specific medical advice, consult a qualified physician. For specific legal advice, consult a qualified attorney.